Equity has deteriorated to -$24.9M from $41.3M in Q1 2024, while total debt fell to $24.6M but the current ratio dropped to 1.36, indicating increased short-term obligations.
Starling Oncology, Inc. (STLN) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 137.69M | 112.75M | 112.42M | 143.49M | 130.42M | 154.06M | 29.72M | 21.79M |
| Cash & Short-Term Investments | 36.9M | 33.56M | 49.67M | 82.86M | 73.81M | 114.3M | 6M | 2.45M |
| Cash Only | 36.9M | 33.56M | 49.67M | 33.49M | 14.01M | 114.3M | 6M | 2.45M |
| Short-Term Investments | 0 | 0 | 0 | 49.37M | 59.8M | 0 | 0 | 0 |
| Accounts Receivable | 60.8M | 59.32M | 48.68M | 42.91M | 40.43M | 21.24M | 17.26M | 14.73M |
| Days Sales Outstanding | 36.22 | 43.07 | 45.17 | 48.31 | 58.45 | 38.2 | 33.59 | 34.61 |
| Inventory | 36.63M | 16.88M | 10.04M | 13.68M | 9.26M | 6.44M | 4.35M | 3.89M |
| Days Inventory Outstanding | 23.65 | 14.45 | 10.8 | 18.86 | 16.87 | 14.49 | 10.55 | 11.31 |
| Other Current Assets | 3.36M | 2.99M | 4.03M | 0 | 0 | 875K | 0 | 0 |
| Total Non-Current Assets | 50.08M | 51.91M | 60.3M | 65.75M | 131.25M | 49.38M | 35.97M | 37.73M |
| Property, Plant & Equipment | 32.57M | 33.06M | 37.67M | 40.05M | 33.04M | 4.19M | 2.1M | 1.55M |
| Fixed Asset Turnover | 19.00x | 15.21x | 10.44x | 8.10x | 7.64x | 48.43x | 89.12x | 100.20x |
| Goodwill | 7.23M | 7.23M | 7.23M | 7.23M | 21.42M | 26.63M | 14.23M | 14.08M |
| Intangible Assets | 8.87M | 11.02M | 14.81M | 17.9M | 17.96M | 18.25M | 19.52M | 22M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 58.35M | -371K | 0 | 0 |
| Other Non-Current Assets | 1.42M | 606K | 589K | 561K | 477K | 320K | 122K | 97.85K |
| Total Assets | 187.77M | 164.66M | 172.72M | 209.24M | 261.67M | 203.44M | 65.69M | 59.52M |
| Asset Turnover | 3.55x | 3.05x | 2.28x | 1.55x | 0.96x | 1.00x | 2.85x | 2.61x |
| Asset Growth % | 14.76% | - | -17.46% | -20.04% | 28.62% | 209.7% | 10.36% | - |
| Total Current Liabilities | 123.7M | 70.96M | 52.22M | 34.79M | 29.72M | 29.8M | 28.61M | 13.59M |
| Accounts Payable | 82.09M | 43.17M | 24.32M | 14.43M | 9.37M | 15.56M | 12.64M | 8.89M |
| Days Payables Outstanding | 56.38 | 36.96 | 26.16 | 19.9 | 17.07 | 35.02 | 30.63 | 25.85 |
| Short-Term Debt | 7.27M | 0 | 0 | 0 | 0 | 183K | 5.37M | 0 |
| Deferred Revenue (Current) | 6.48M | 2.28M | 4.7M | 545K | 1.14M | 592K | 3.38M | 0 |
| Other Current Liabilities | 116.43M | 13.15M | 10.35M | 11.32M | 9.35M | 10.14M | -3.38M | 0 |
| Current Ratio | 1.11x | 1.59x | 2.15x | 4.12x | 4.39x | 5.17x | 1.04x | 1.60x |
| Quick Ratio | 0.82x | 1.35x | 1.96x | 3.73x | 4.08x | 4.95x | 0.89x | 1.32x |
| Cash Conversion Cycle | 3.49 | 20.56 | 29.8 | 47.27 | 58.25 | 17.67 | 13.51 | 20.07 |
| Total Non-Current Liabilities | 101.43M | 109.41M | 116.91M | 117.43M | 108.77M | 69.48M | 8.98M | 3.71M |
| Long-Term Debt | 17.94M | 77.4M | 93.13M | 86.83M | 80.62M | 0 | 6.56M | 0 |
| Capital Lease Obligations | 55.36M | 19.13M | 23.22M | 26.49M | 22.06M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 32K | 32K | 108K | 371K | 1.61M | 2.96M |
| Other Non-Current Liabilities | 83.49M | 12.88M | 527K | 4.08M | 5.98M | 69.11M | 807K | 756.42K |
| Total Liabilities | 225.13M | 180.38M | 169.13M | 152.22M | 138.49M | 99.28M | 37.59M | 17.3M |
| Total Debt | 25.21M | 103.69M | 123.15M | 119.67M | 108.18M | 183K | 11.93M | 0 |
| Net Debt | -11.69M | 70.12M | 73.48M | 86.19M | 94.17M | -114.12M | 5.93M | -2.45M |
| Debt / Equity | -0.67x | - | 34.31x | 2.10x | 0.88x | 0.00x | 0.42x | - |
| Debt / EBITDA | -1.75x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.81x | - | - | - | - | - | - | -8.23x |
| Interest Coverage | -1.87x | -4.39x | -7.63x | -8.88x | -17.64x | -141.82x | -41.69x | -780.67x |
| Total Equity | -37.35M | -15.72M | 3.59M | 57.02M | 123.17M | 104.16M | 28.1M | 42.22M |
| Equity Growth % | -204.34% | - | -93.71% | -53.7% | 18.26% | 270.66% | -33.45% | - |
| Book Value per Share | -0.04 | -0.17 | 0.05 | 0.77 | 1.53 | 1.57 | 0.48 | 0.66 |
| Total Shareholders' Equity | -37.35M | -15.72M | 3.59M | 57.02M | 123.17M | 104.16M | 28.1M | 42.22M |
| Common Stock | 10K | 10K | 8K | 8K | 7K | 7K | 6K | 0 |
| Retained Earnings | -299.45M | -271.42M | -210.81M | -146.15M | -63.08M | -63.23M | -52.31M | -6.02M |
| Treasury Stock | 0 | -1.02M | -1.02M | -1.02M | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying STLN stock.
As of 2025, Starling Oncology, Inc. (STLN) had total assets of $164.7M including $112.7M in current assets.
Starling Oncology, Inc. (STLN) carries total debt of $103.7M, offset by $33.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Starling Oncology, Inc. (STLN) has total shareholders' equity (book value) of $-15.7M ($-0.17 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Starling Oncology, Inc. (STLN) reported a current ratio of 1.59x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative equity and high debt
Metrics are mathematically derived from official filings.
Equity Erosion Accelerates
TOI's equity deteriorated from $41.3M in 2024Q1 to -$24.9M by 2026Q2, a swing of $66.2M, as cumulative losses outpaced any capital raises, per quarterly balance sheet data.
The balance sheet is clearly weakening, with total liabilities growing from $163.2M to $203.1M while assets contracted from $204.5M to $178.2M over the same period. This divergence suggests the company is funding operations through debt and other liabilities, not equity, which may indicate a reliance on external financing to sustain growth. The trend implies that without a significant improvement in profitability or a capital infusion, the negative equity position could worsen, potentially straining future financing options.
Debt Load Shifts to Short-Term
Total debt fell from $119.8M in 2024Q1 to $24.6M in 2026Q2, but the current ratio dropped from 3.08 to 1.36, indicating a shift toward short-term obligations, per reported figures.
While the absolute debt reduction appears positive, the concurrent decline in the current ratio from 3.08 to 1.36 suggests that the composition of liabilities has become more immediate, possibly reflecting increased accounts payable or accrued expenses. The D/E ratio is not calculable in recent quarters due to negative equity, but the earlier D/E of 20.18 in 2025Q1 highlights the extreme leverage when equity was minimal. This may indicate that the company is managing its debt by converting long-term obligations into short-term ones, which could heighten refinancing risk if liquidity tightens.
Asset Base Shrinks with Stable Intangibles
Total assets declined from $204.5M to $178.2M over ten quarters, while goodwill remained constant at $7.2M and PPE net fell from $38.4M to $31.8M, per balance sheet data.
The reduction in total assets is driven primarily by a decline in PPE, which may indicate underinvestment in fixed assets or asset sales, consistent with an asset-light model. Goodwill has remained unchanged, suggesting no impairments have been recorded, but the stable goodwill against a shrinking asset base increases its relative weight, potentially raising impairment risk if the company's market value continues to lag. The asset mix appears to be shifting toward more current assets, which could improve liquidity but may also reflect a lack of long-term investment.
Retained Losses Consume Equity
Accumulated deficit grew from -$166.0M to -$283.7M over ten quarters, driving equity from $41.3M to -$24.9M, with no dividends or buybacks, as per financial statements.
The equity deterioration is almost entirely attributable to retained losses, which have grown by $117.7M over the period, far exceeding any capital contributions. The absence of share repurchases or dividends indicates that all cash is being retained for operations, yet the losses continue to erode the equity base. This suggests that the company's growth strategy is heavily dependent on external financing, and the negative equity position may limit its ability to raise additional equity without diluting existing shareholders.
Liquidity Buffer Thins
Cash increased from $36.1M to $41.1M, but the current ratio fell from 3.08 to 1.36, and cash relative to total liabilities dropped from 22% to 20%, per reported data.
While cash has grown modestly, the current ratio has nearly halved, indicating that current liabilities are growing faster than current assets. This suggests that the company's liquidity buffer is thinning relative to its short-term obligations, which could increase vulnerability to cash flow disruptions. The cash position of $41.1M against a quarterly operating loss of around $10M provides a runway of roughly four quarters, but the reliance on working capital swings for positive cash flow in 2026Q2 implies that this runway could be shorter if those swings reverse.
Negative Equity Masks Debt Reduction
Despite a $95.2M reduction in total debt, equity turned negative at -$24.9M, suggesting the debt paydown may have been funded by liquidating assets or increasing other liabilities, per balance sheet data.
The headline improvement in total debt from $119.8M to $24.6M is overshadowed by the fact that equity has swung to a deficit, and total liabilities have actually increased from $163.2M to $203.1M. This implies that the debt reduction may have been achieved by converting debt into other forms of liabilities, such as accounts payable or accrued expenses, rather than through genuine deleveraging. Investors should monitor the composition of liabilities and the sustainability of the current ratio, as the apparent debt reduction may not reflect an improvement in financial health.